Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

The Clinical Cancer Letter, March 2011, vol. 34 no. 3

publication date: Mar 31, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
  • Rituximab and Fludarabine combination produces long-term remissions in CLL
  • Two-year remission while taking Gleevec puts patients into normal mortality rate for CML
  • DCIS: Radiation and Tamoxifen after lumpectomy reduces cancer recurrence
  • Dendritic cell vaccine may boost survival of glioblastoma
  • Multiple Births increases risk for triple-negative breast cancer
  • Statins associated with lower risk of high-grade prostate cancer


To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.